Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$3.33 USD
+0.05 (1.47%)
Updated Oct 18, 2024 03:56 PM ET
After-Market: $3.30 -0.03 (-0.90%) 5:40 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Acasti Pharma, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 23 | 28 | 44 | 61 | 14 |
Receivables | 1 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 24 | 29 | 46 | 62 | 16 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 49 | 49 | 83 | 0 | 4 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 73 | 79 | 129 | 62 | 23 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 3 | 1 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 3 | 2 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 7 | 17 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 0 | 0 | 5 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 11 | 20 | 7 | 10 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 261 | 258 | 258 | 197 | 137 |
Capital Surplus | 18 | 14 | 12 | 11 | 10 |
Retained Earnings | -211 | -198 | -156 | -146 | -126 |
Other Equity | -6 | -6 | -6 | -6 | -8 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 62 | 68 | 108 | 56 | 13 |
Total Liabilities & Shareholder's Equity | 73 | 79 | 129 | 62 | 23 |
Total Common Equity | 62 | 68 | 108 | 56 | 13 |
Shares Outstanding | 9.40 | 7.40 | 7.30 | 4.30 | 1.80 |
Book Value Per Share | 6.57 | 9.18 | 14.83 | 12.94 | 7.22 |
Fiscal Year End for Acasti Pharma, Inc falls in the month of March.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 19 | 23 | 25 | 27 |
Receivables | NA | 0 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 1 | 1 |
Total Current Assets | NA | 20 | 24 | 27 | 29 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 49 | 49 | 49 | 49 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 70 | 73 | 76 | 78 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 2 | 2 | 1 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 6 | 6 | 7 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 3 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 10 | 12 | 12 | 11 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 261 | 261 | 261 | 261 |
Capital Surplus | NA | 18 | 18 | 18 | 17 |
Retained Earnings | NA | -214 | -211 | -208 | -206 |
Other Equity | NA | -6 | -6 | -6 | -6 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 59 | 62 | 65 | 67 |
Total Liabilities & Shareholder's Equity | NA | 70 | 73 | 76 | 78 |
Total Common Equity | 0 | 59 | 62 | 65 | 67 |
Shares Outstanding | 10.10 | 10.10 | 9.40 | 9.40 | 7.40 |
Book Value Per Share | 0.00 | 5.88 | 6.57 | 6.88 | 9.02 |